The British Journal of Psychiatry
February 1, 2016
Robert A Schoevers, Tharcila V. Chaves, Sonya M. Balukova et al.
80 citations
BACKGROUND: Recent studies with intravenous (i.v.) application of ketamine show remarkable but short-term success in patients with MDD. Studies in patients with chronic pain have used different ketamine applications for longer time periods. This experience may be relevant for psychiatric indications. AIMS: To review the literature about the dosing regimen, duration, effects and side-effects of...
Journal of Affective Disorders
January 15, 2016
Megha M Vasavada, Amber M Leaver, Randall Espinoza et al.
58 citations
Ketamine elicits an acute antidepressant effect in patients with major depressive disorder (MDD). Here, we used diffusion imaging to explore whether regional differences in white matter microstructure prior to treatment may predict clinical response 24h following ketamine infusion in 10 MDD patients. FSL's Tract-Based Spatial Statistics (TBSS) established voxel-level differences in fractional...
BMC Medical Ethics
January 14, 2016
Melvyn W B Zhang, Keith M. Harris, Roger Ho
69 citations
BACKGROUND: Depressive disorders are a common form of psychiatric illness and cause significant disability. Regulation authorities, the medical profession and the public require high safety standards for antidepressants to protect vulnerable psychiatric patients. Ketamine is a dissociative anaesthetic and a derivative of a hallucinogen (phencyclidine). Its abuse is a major worldwide public...
The World Journal of Biological Psychiatry
January 11, 2016
Matthew N. Cooper, Joshua D. Rosenblat, Danielle S. Cha et al.
40 citations
Objectives Replicated evidence has demonstrated that ketamine exerts rapid-acting and potent antidepressant effects. Notwithstanding, its promise to mitigate depressive symptoms and suicidality in antidepressant-resistant populations, several limitations and safety concerns accompany ketamine including, but not limited to, the potential for abuse and psychotomimetic/dissociative experiences....
2016
Mingfa Huang, Ke Zhang, Xiang Cai
The mechanisms underlying the rapid-acting antidepressant effects of ketamine have not been fully identified. In current study, we observed that a single subanesthesia dose of ketamine strongly decreased the immobility time of Sprague–Dawley rats in forced swim test. Ketamine injection significantly increased GluR1 expression and GluR1 Ser845 phosphorylation in prefrontal cortex....
International Journal on Disability and Human Development
2016
Theodore Kastner, Kevin Walsh, Lisa Shulman et al.
Abstract: Autism or autism spectrum disorder (ASD) is a behavioral syndrome characterized by (a) persistent deficits in social communication and social interaction across multiple contexts and (b) restricted, repetitive patterns of behavior, interests or activities. However, the etiology of autism in most cases remains unknown. Ketamine, an N-Methyl-D-aspartate (NMDA) blocker, has been...
2016
Michael A. Cerullo, A. Stryker
In severe depression thoughts of suicide can develop over weeks or months. Traditional pharmacologic or psychotherapeutic treatments take several weeks before they begin to improve symptoms. This gradual improvement is consistent with our everyday experience of the self. However, a new treatment, ketamine, can alter depressive symptoms within hours or even minutes. Ketamine can stop suicidal...
The American Journal of Bioethics
2016
Michael H Andreae, Evelyn Rhodes, Tyler Bourgoise et al.
We examine the ethical, social, and regulatory barriers that may hinder research on therapeutic potential of certain controversial controlled substances like marijuana, heroin, or ketamine. Hazards for individuals and society and potential adverse effects on communities may be good reasons for limiting access and justify careful monitoring of these substances. Overly strict regulations, fear of...
The Brown University Psychopharmacology Update
2016
A review and meta‐analysis of the effects of N‐methyl‐D‐aspartate (NMDA) receptor antagonists in treating major depression has confirmed that ketamine is the only such drug to date that has demonstrated antidepressant efficacy across multiple trials. Authors of the review stated, however, that the findings regarding ketamine should be viewed with caution because the beneficial effects are not...
PeerJ
2016
Jing J Wong, Owen O'Daly, Mitul A. Mehta et al.
Background. Ketamine has been reported to have efficacy as an antidepressant in several studies of treatment-resistant depression. In this study, we investigate whether an acute administration of ketamine leads to reductions in the functional connectivity of subgenual anterior cingulate cortex (sgACC) with other brain regions. Methods. Thirteen right-handed healthy male subjects underwent a 15...
Indian Journal of Psychological Medicine
2016
Mahesh Ramanna Gowda, Preethi Srinivasa, Prabha S Kumbar et al.
Ketamine, a primarily FDA-approved anaesthetic agent is also used as recreational drug. Based on preclinical findings and later the clinical observations it is noted to have rapid antidepressant effect due to its mechanisms related to NMDA antagonism. In spite of established evidence of ketamine being effective in depression with significant role in treatment resistant cases as well, there was...
Case Reports in Neurology
2016
Scott J Sherman, Miguel Estevez, Ari B Magill et al.
Ketamine is an FDA-approved drug with a known safety profile. Low-dose subanesthetic intravenous ketamine infusion treatment has led to long-term reduction of treatment-resistant depression and of chronic pain states. We report on low-dose subanesthetic intravenous ketamine infusion treatment in Parkinson's disease (PD) patients by 5 case studies and show a long-lasting therapeutic benefit to...
Neuropsychiatric Disease and Treatment
2016
Yuan-Yuan Lu, Chieh-Hsin Lin, Hsien-Yuan Lane
17 citations
Ketamine, a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, has multiple clinical uses. On the other hand, ketamine abuse or recreational use has been gaining increasing attention. Induction of mania and psychotic symptoms has been reported in a patient receiving IV ketamine therapy for reflex sympathetic dystrophy. We here report a 26 year-old man who abused ketamine by...